News

Novozymes supplies Chinese pioneer
Enlarge image

BusinessSweden

Novozymes supplies Chinese pioneer

17.06.2012 - The Danish world market leader in enzyme technology, Novozymes A/S, will supply a large scale bioethanol production plant in China.

Baegsvaard – The deal was agreed during a visit from Hu Jintao, President of the People's Republic of China, in Copenhagen. Novozymes and its partner Shenqquan first announced the deal last month. China's Shengquan Group will start producing cellulosic ethanol in July, the company said.  According to Shenqquan, it will be the first in the world to do so on a commercial scale. The production will also be cost-competitive given that the feedstock, conventional ethanol, is a waste product from Shengquan's current production. The Chinese company is investing US $100m in the new groundbreaking facility. Novozymes will supply the enabling enzyme technology.

"When Shengquan opens its facility next month, it will be the first in the world," explains Steen Riisgaard, President and CEO of Novozymes. "It's fantastic to finally see this industry go commercial; for more than 10 years our researchers have worked to bring down the cost of producing ethanol from agricultural residues and household and industrial waste." Shengquan is a producer of furfural for resin production in the foundry industry. Furfural is produced from corncob xylose, with the cellulose from the corncob left behind as a waste product. Using Novozymes' enzymes, Shengquan will now be able to convert the cellulose into higher-value sugars that can be fermented to ethanol.  Shengquan will market the ethanol as an industrial solvent. "In order to continue to grow our country's economy at the same time as reducing our dependency on natural resources and minimizing the environmental impact, we need to start thinking of waste as an extremely valuable resource," comments Yi Lin Tang, President and Chairman of Shengquan Group. "Basically, we want and need to nurture a green and circular bioeconomy which is less dependent on fossil resources."

http://www.european-biotechnology-news.com/news/news/2012-02/novozymes-supplies-chinese-pioneer.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE12.51 EUR18.92%
  • CO.DON2.88 EUR9.09%
  • FORMYCON26.77 EUR8.91%

FLOP

  • 4SC1.16 EUR-7.20%
  • MOLOGEN5.69 EUR-2.07%
  • CYTOS1.43 CHF-1.38%

TOP

  • CYTOS1.43 CHF320.6%
  • MEDIGENE12.51 EUR194.4%
  • FORMYCON26.77 EUR60.3%

FLOP

  • MORPHOSYS60.10 EUR-19.6%
  • BASILEA108.20 CHF-11.5%
  • WILEX3.10 EUR-9.6%

TOP

  • SANTHERA96.50 CHF2312.5%
  • FORMYCON26.77 EUR271.8%
  • WILEX3.10 EUR198.1%

FLOP

  • CYTOS1.43 CHF-52.5%
  • MOLOGEN5.69 EUR-49.4%
  • PAION2.53 EUR-24.0%

No liability assumed, Date: 30.03.2015